Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Sands, Bruce E; D'Haens, Geert; Clemow, David B; Irving, Peter M; Johns, Jordan T; Gibble, Theresa Hunter; Abreu, Maria T; Lee, Scott; Hisamatsu, Tadakazu; Kobayashi, Taku; Dubinsky, Marla C; Vermeire, Severine; Siegel, Corey A; Peyrin-Biroulet, Laurent; Moses, Richard E; Milata, Joe; Arora, Vipin; Panaccione, Remo; Dignass, Axel

doi:10.1093/ibd/izae024

Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study

Author:

Sands, Bruce E

D'Haens, Geert ; Clemow, David B ; Irving, Peter M ; Johns, Jordan T ; Gibble, Theresa Hunter ; Abreu, Maria T ; Lee, Scott ; Hisamatsu, Tadakazu ; Kobayashi, Taku ; Dubinsky, Marla C ; Vermeire, Severine ; Siegel, Corey A ; Peyrin-Biroulet, Laurent ; Moses, Richard E ; Milata, Joe ; Arora, Vipin ; Panaccione, Remo ; Dignass, Axel

Keywords:

Science & Technology, Life Sciences & Biomedicine, Gastroenterology & Hepatology, mirikizumab, ulcerative colitis, IL-23 p19 antibody, long-term extension, week 104 results, QUALITY-OF-LIFE, DISEASE, LAW, 1103 Clinical Sciences, 3202 Clinical sciences